FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800351065> ?p ?o ?g. }

• W2800351065 endingPage "105" @default.
• W2800351065 startingPage "95" @default.
• W2800351065 abstract "This multicenter cooperative study aimed to analyze the adverse events (AEs) associated with tyrosine kinase inhibitors (TKIs) used as initial treatment for chronic-phase chronic myeloid leukemia (CML-CP) and their impact on outcome.We retrospectively evaluated 450 patients with CML-CP who received TKIs between 2004 and 2014.The 5-year overall survival (OS) and event-free survival (EFS) rates were 95.1% and 89.0%, respectively. Patients with comorbidities (46.4%) and aged ≥60 years (50.4%) at diagnosis had significantly inferior OS to those without comorbidities and aged <60. Patients achieved higher rates of major molecular response (MMR) at 6 and 12 months after initial treatment with dasatinib or nilotinib compared to imatinib, but final MMR rates were almost the same. Sixty-six percent of patients required treatment modifications from first-line TKI therapy; the main reasons were AEs (48.4%) and failure (18%). Grade III-IV AEs in first-line TKI therapy were significantly correlated to inferior OS/EFS compared to grade 0-II AEs.Although long-term outcomes were similar in CML-CP patients treated with each TKI regardless of first-line TKI selection, severe AEs in first-line TKI therapy decreased their survival rates. Early change in TKIs is recommended, when faced with severe AEs of specific TKIs." @default.
• W2800351065 created "2018-05-17" @default.
• W2800351065 creator A5001474799 @default.
• W2800351065 creator A5003448058 @default.
• W2800351065 creator A5004365170 @default.
• W2800351065 creator A5004952308 @default.
• W2800351065 creator A5009062230 @default.
• W2800351065 creator A5009749245 @default.
• W2800351065 creator A5013706862 @default.
• W2800351065 creator A5018025310 @default.
• W2800351065 creator A5018073323 @default.
• W2800351065 creator A5020000986 @default.
• W2800351065 creator A5022406738 @default.
• W2800351065 creator A5028305352 @default.
• W2800351065 creator A5034892457 @default.
• W2800351065 creator A5035118858 @default.
• W2800351065 creator A5038310819 @default.
• W2800351065 creator A5044690140 @default.
• W2800351065 creator A5049803192 @default.
• W2800351065 creator A5051449739 @default.
• W2800351065 creator A5051586702 @default.
• W2800351065 creator A5053000890 @default.
• W2800351065 creator A5054315130 @default.
• W2800351065 creator A5057460944 @default.
• W2800351065 creator A5064125582 @default.
• W2800351065 creator A5064182775 @default.
• W2800351065 creator A5072326450 @default.
• W2800351065 creator A5076849586 @default.
• W2800351065 date "2018-05-23" @default.
• W2800351065 modified "2023-10-12" @default.
• W2800351065 title "Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia" @default.
• W2800351065 cites W1495300968 @default.
• W2800351065 cites W1703585081 @default.
• W2800351065 cites W1939978733 @default.
• W2800351065 cites W1973595070 @default.
• W2800351065 cites W1978821257 @default.
• W2800351065 cites W1987060661 @default.
• W2800351065 cites W1993702149 @default.
• W2800351065 cites W2010678043 @default.
• W2800351065 cites W2014933948 @default.
• W2800351065 cites W2016933020 @default.
• W2800351065 cites W2055515709 @default.
• W2800351065 cites W2057206328 @default.
• W2800351065 cites W2058216377 @default.
• W2800351065 cites W2072834954 @default.
• W2800351065 cites W2073587057 @default.
• W2800351065 cites W2085342571 @default.
• W2800351065 cites W2097799776 @default.
• W2800351065 cites W2119900325 @default.
• W2800351065 cites W2121960517 @default.
• W2800351065 cites W2160811827 @default.
• W2800351065 cites W2258178934 @default.
• W2800351065 cites W2260921597 @default.
• W2800351065 cites W2261840157 @default.
• W2800351065 cites W2271377711 @default.
• W2800351065 cites W2397234997 @default.
• W2800351065 cites W2443078590 @default.
• W2800351065 cites W2587781815 @default.
• W2800351065 cites W2592060299 @default.
• W2800351065 cites W2597372376 @default.
• W2800351065 cites W2599551048 @default.
• W2800351065 cites W2604779344 @default.
• W2800351065 doi "https://doi.org/10.1111/ejh.13081" @default.
• W2800351065 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29660177" @default.
• W2800351065 hasPublicationYear "2018" @default.
• W2800351065 type Work @default.
• W2800351065 sameAs 2800351065 @default.
• W2800351065 citedByCount "14" @default.
• W2800351065 countsByYear W28003510652018 @default.
• W2800351065 countsByYear W28003510652019 @default.
• W2800351065 countsByYear W28003510652020 @default.
• W2800351065 countsByYear W28003510652021 @default.
• W2800351065 countsByYear W28003510652022 @default.
• W2800351065 countsByYear W28003510652023 @default.
• W2800351065 crossrefType "journal-article" @default.
• W2800351065 hasAuthorship W2800351065A5001474799 @default.
• W2800351065 hasAuthorship W2800351065A5003448058 @default.
• W2800351065 hasAuthorship W2800351065A5004365170 @default.
• W2800351065 hasAuthorship W2800351065A5004952308 @default.
• W2800351065 hasAuthorship W2800351065A5009062230 @default.
• W2800351065 hasAuthorship W2800351065A5009749245 @default.
• W2800351065 hasAuthorship W2800351065A5013706862 @default.
• W2800351065 hasAuthorship W2800351065A5018025310 @default.
• W2800351065 hasAuthorship W2800351065A5018073323 @default.
• W2800351065 hasAuthorship W2800351065A5020000986 @default.
• W2800351065 hasAuthorship W2800351065A5022406738 @default.
• W2800351065 hasAuthorship W2800351065A5028305352 @default.
• W2800351065 hasAuthorship W2800351065A5034892457 @default.
• W2800351065 hasAuthorship W2800351065A5035118858 @default.
• W2800351065 hasAuthorship W2800351065A5038310819 @default.
• W2800351065 hasAuthorship W2800351065A5044690140 @default.
• W2800351065 hasAuthorship W2800351065A5049803192 @default.
• W2800351065 hasAuthorship W2800351065A5051449739 @default.
• W2800351065 hasAuthorship W2800351065A5051586702 @default.
• W2800351065 hasAuthorship W2800351065A5053000890 @default.
• W2800351065 hasAuthorship W2800351065A5054315130 @default.
• W2800351065 hasAuthorship W2800351065A5057460944 @default.
• W2800351065 hasAuthorship W2800351065A5064125582 @default.

• next